GHSG trials, cHL patient characteristics, and association with serum Gal1 levels
| . | Patients . | (%) . | Gal1 (ng/mL)* . | P value . |
|---|---|---|---|---|
| All patients | 293 | (100) | 93.0 ± 56.5 | |
| Trial/risk group | .0002 | |||
| HD13/favorable | 80 | (27.3) | 71.6 ± 39.7 | |
| HD14/intermediate | 89 | (30.4) | 97.4 ± 54.3 | |
| HD18/unfavorable | 124 | (42.3) | 103.7 ± 63.4 | |
| Age | NS | |||
| ≥45 y | 65 | (22.2) | 62.8 ± 43.0 | |
| <45 y | 228 | (77.8) | 90.4 ± 55.9 | |
| Gender | NS | |||
| Male | 156 | (53.2) | 92.8 ± 57.1 | |
| Female | 137 | (46.8) | 89.6 ± 53.6 | |
| Histologic type | NS | |||
| Nodular sclerosis | 151 | (51.5) | 95.9 ± 55.9 | |
| Mixed cellularity | 64 | (21.8) | 96.2 ± 60.9 | |
| Lymphocyte rich | 12 | (4.1) | 79.1 ± 43.3 | |
| Unclassified | 66 | (22.5) | 76.7 ± 43.8 | |
| Ann Arbor stage | .012 | |||
| I | 32 | (10.9) | 72.7 ± 42.0 | |
| II | 151 | (51.5) | 88.9 ± 53.7 | |
| III | 53 | (18.1) | 96.5 ± 45.8 | |
| IV | 46 | (15.7) | 116.4 ± 76.5 | |
| Unknown† | 11 | (3.8) | ||
| B symptoms | .047 | |||
| Absence | 168 | (57.3) | 85.3 ± 47.1 | |
| Presence | 114 | (38.9) | 104.1 ± 67.1 | |
| Unknown† | 11 | (3.8) | ||
| IPS | .019 | |||
| 0 or 1 | 134 | (45.7) | 82.4 ± 44.0 | |
| 2-7 | 128 | (43.7) | 103.7 ± 66.0 | |
| Unknown† | 31 | (10.6) | ||
| Individual IPS risk factors | ||||
| Extranodal involvement (stage IV) | .011 | |||
| Absence | 249 | (85.0) | 89.2 ± 54.3 | |
| Presence | 35 | (11.9) | 116.3 ± 67.2 | |
| Unknown† | 9 | (3.1) | ||
| Lymphocyte count, <600/mm3 or <8% of total white-cell count | .036 | |||
| Absence | 269 | (91.8) | 91.2 ± 56.2 | |
| Presence | 13 | (4.4) | 124.9 ± 62.9 | |
| Unknown† | 11 | (3.8) | ||
| Additional prognostic factors | ||||
| Number of involved lymph node sites ≥3 | <.0001 | |||
| Absence | 120 | (41.0) | 78.6 ± 49.0 | |
| Presence | 165 | (56.3) | 102.7 ± 59.6 | |
| Unknown† | 8 | (2.7) | ||
| Elevated erythrocyte sedimentation rate (ESR) | .007 | |||
| Absence | 148 | (50.5) | 82.1 ± 45.3 | |
| Presence | 134 | (45.7) | 104.1 ± 65.6 | |
| Unknown† | 11 | (3.8) | ||
| . | Patients . | (%) . | Gal1 (ng/mL)* . | P value . |
|---|---|---|---|---|
| All patients | 293 | (100) | 93.0 ± 56.5 | |
| Trial/risk group | .0002 | |||
| HD13/favorable | 80 | (27.3) | 71.6 ± 39.7 | |
| HD14/intermediate | 89 | (30.4) | 97.4 ± 54.3 | |
| HD18/unfavorable | 124 | (42.3) | 103.7 ± 63.4 | |
| Age | NS | |||
| ≥45 y | 65 | (22.2) | 62.8 ± 43.0 | |
| <45 y | 228 | (77.8) | 90.4 ± 55.9 | |
| Gender | NS | |||
| Male | 156 | (53.2) | 92.8 ± 57.1 | |
| Female | 137 | (46.8) | 89.6 ± 53.6 | |
| Histologic type | NS | |||
| Nodular sclerosis | 151 | (51.5) | 95.9 ± 55.9 | |
| Mixed cellularity | 64 | (21.8) | 96.2 ± 60.9 | |
| Lymphocyte rich | 12 | (4.1) | 79.1 ± 43.3 | |
| Unclassified | 66 | (22.5) | 76.7 ± 43.8 | |
| Ann Arbor stage | .012 | |||
| I | 32 | (10.9) | 72.7 ± 42.0 | |
| II | 151 | (51.5) | 88.9 ± 53.7 | |
| III | 53 | (18.1) | 96.5 ± 45.8 | |
| IV | 46 | (15.7) | 116.4 ± 76.5 | |
| Unknown† | 11 | (3.8) | ||
| B symptoms | .047 | |||
| Absence | 168 | (57.3) | 85.3 ± 47.1 | |
| Presence | 114 | (38.9) | 104.1 ± 67.1 | |
| Unknown† | 11 | (3.8) | ||
| IPS | .019 | |||
| 0 or 1 | 134 | (45.7) | 82.4 ± 44.0 | |
| 2-7 | 128 | (43.7) | 103.7 ± 66.0 | |
| Unknown† | 31 | (10.6) | ||
| Individual IPS risk factors | ||||
| Extranodal involvement (stage IV) | .011 | |||
| Absence | 249 | (85.0) | 89.2 ± 54.3 | |
| Presence | 35 | (11.9) | 116.3 ± 67.2 | |
| Unknown† | 9 | (3.1) | ||
| Lymphocyte count, <600/mm3 or <8% of total white-cell count | .036 | |||
| Absence | 269 | (91.8) | 91.2 ± 56.2 | |
| Presence | 13 | (4.4) | 124.9 ± 62.9 | |
| Unknown† | 11 | (3.8) | ||
| Additional prognostic factors | ||||
| Number of involved lymph node sites ≥3 | <.0001 | |||
| Absence | 120 | (41.0) | 78.6 ± 49.0 | |
| Presence | 165 | (56.3) | 102.7 ± 59.6 | |
| Unknown† | 8 | (2.7) | ||
| Elevated erythrocyte sedimentation rate (ESR) | .007 | |||
| Absence | 148 | (50.5) | 82.1 ± 45.3 | |
| Presence | 134 | (45.7) | 104.1 ± 65.6 | |
| Unknown† | 11 | (3.8) | ||